Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 74

1.

PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer.

Sau S, Petrovici A, Alsaab HO, Bhise K, Iyer AK.

Cancers (Basel). 2019 Feb 16;11(2). pii: E232. doi: 10.3390/cancers11020232.

2.

pH triggered and charge attracted nanogel for simultaneous evaluation of penetration and toxicity against skin cancer: In-vitro and ex-vivo study.

Sahu P, Kashaw SK, Sau S, Kushwah V, Jain S, Agrawal RK, Iyer AK.

Int J Biol Macromol. 2019 May 1;128:740-751. doi: 10.1016/j.ijbiomac.2019.01.147. Epub 2019 Jan 27.

PMID:
30699336
3.

Development of asialoglycoprotein receptor directed nanoparticles for selective delivery of curcumin derivative to hepatocellular carcinoma.

Yousef S, Alsaab HO, Sau S, Iyer AK.

Heliyon. 2018 Dec 22;4(12):e01071. doi: 10.1016/j.heliyon.2018.e01071. eCollection 2018 Dec.

4.

pH Responsive 5-Fluorouracil Loaded Biocompatible Nanogels For Topical Chemotherapy of Aggressive Melanoma.

Sahu P, Kashaw SK, Sau S, Kushwah V, Jain S, Agrawal RK, Iyer AK.

Colloids Surf B Biointerfaces. 2019 Feb 1;174:232-245. doi: 10.1016/j.colsurfb.2018.11.018. Epub 2018 Nov 10.

PMID:
30465998
5.

Exploring the role of water molecules in the ligand binding domain of PDE4B and PDE4D:Virtual screening based molecular docking of some active scaffolds.

Singh P, Mishra M, Agarwal S, Sau S, Iyer AK, Kashaw SK.

Curr Comput Aided Drug Des. 2018 Nov 5. doi: 10.2174/1573409914666181105153543. [Epub ahead of print]

PMID:
30394213
6.

Molecular Docking Analysis of Caspase-3 Activators as Potential Anticancer Agents.

Kashaw SK, Agarwal S, Mishra M, Sau S, Iyer AK.

Curr Comput Aided Drug Des. 2019;15(1):55-66. doi: 10.2174/1573409914666181015150731.

PMID:
30324892
7.

Immunotherapy and molecular role of T-cell in PD-1 antibody treated resectable lung cancer patients.

Sau S, Iyer AK.

J Thorac Dis. 2018 Aug;10(8):4682-4685. doi: 10.21037/jtd.2018.07.66. No abstract available.

8.

Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages.

Alsaab HO, Sau S, Alzhrani RM, Cheriyan VT, Polin LA, Vaishampayan U, Rishi AK, Iyer AK.

Biomaterials. 2018 Nov;183:280-294. doi: 10.1016/j.biomaterials.2018.08.053. Epub 2018 Aug 30.

PMID:
30179778
9.

Nano-engineered delivery systems for cancer imaging and therapy: Recent advances, future direction and patent evaluation.

Nabil G, Bhise K, Sau S, Atef M, El-Banna HA, Iyer AK.

Drug Discov Today. 2019 Feb;24(2):462-491. doi: 10.1016/j.drudis.2018.08.009. Epub 2018 Aug 16. Review.

PMID:
30121330
10.

A CARP-1 functional mimetic compound is synergistic with BRAF-targeting in non-small cell lung cancers.

Cheriyan VT, Alsaab H, Sekhar S, Venkatesh J, Mondal A, Vhora I, Sau S, Muthu M, Polin LA, Levi E, Bepler G, Iyer AK, Singh M, Rishi AK.

Oncotarget. 2018 Jul 3;9(51):29680-29697. doi: 10.18632/oncotarget.25671. eCollection 2018 Jul 3.

11.

Combination of Vancomycin and Cefazolin Lipid Nanoparticles for Overcoming Antibiotic Resistance of MRSA.

Bhise K, Sau S, Kebriaei R, Rice SA, Stamper KC, Alsaab HO, Rybak MJ, Iyer AK.

Materials (Basel). 2018 Jul 20;11(7). pii: E1245. doi: 10.3390/ma11071245.

12.

An integrated computational approach of molecular dynamics simulations, receptor binding studies and pharmacophore mapping analysis in search of potent inhibitors against tuberculosis.

Agarwal S, Verma E, Kumar V, Lall N, Sau S, Iyer AK, Kashaw SK.

J Mol Graph Model. 2018 Aug;83:17-32. doi: 10.1016/j.jmgm.2018.04.019. Epub 2018 May 3.

PMID:
29753941
13.

CD44 directed nanomicellar payload delivery platform for selective anticancer effect and tumor specific imaging of triple negative breast cancer.

Wang Z, Sau S, Alsaab HO, Iyer AK.

Nanomedicine. 2018 Jun;14(4):1441-1454. doi: 10.1016/j.nano.2018.04.004. Epub 2018 Apr 17.

PMID:
29678787
14.

Paclitaxel and di-fluorinated curcumin loaded in albumin nanoparticles for targeted synergistic combination therapy of ovarian and cervical cancers.

Gawde KA, Sau S, Tatiparti K, Kashaw SK, Mehrmohammadi M, Azmi AS, Iyer AK.

Colloids Surf B Biointerfaces. 2018 Jul 1;167:8-19. doi: 10.1016/j.colsurfb.2018.03.046. Epub 2018 Mar 28.

PMID:
29625422
15.

A tumor multicomponent targeting chemoimmune drug delivery system for reprograming the tumor microenvironment and personalized cancer therapy.

Sau S, Tatiparti K, Alsaab HO, Kashaw SK, Iyer AK.

Drug Discov Today. 2018 Jul;23(7):1344-1356. doi: 10.1016/j.drudis.2018.03.003. Epub 2018 Mar 15. Review.

PMID:
29551455
16.
17.

Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment.

Sau S, Alsaab HO, Bhise K, Alzhrani R, Nabil G, Iyer AK.

J Control Release. 2018 Mar 28;274:24-34. doi: 10.1016/j.jconrel.2018.01.028. Epub 2018 Jan 31. Review.

18.

A CARP-1 functional mimetic loaded vitamin E-TPGS micellar nano-formulation for inhibition of renal cell carcinoma.

Cheriyan VT, Alsaab HO, Sekhar S, Stieber C, Kesharwani P, Sau S, Muthu M, Polin LA, Levi E, Iyer AK, Rishi AK.

Oncotarget. 2017 Sep 5;8(62):104928-104945. doi: 10.18632/oncotarget.20650. eCollection 2017 Dec 1.

19.

Nanomedicine for cancer diagnosis and therapy: advancement, success and structure-activity relationship.

Bhise K, Sau S, Alsaab H, Kashaw SK, Tekade RK, Iyer AK.

Ther Deliv. 2017 Nov;8(11):1003-1018. doi: 10.4155/tde-2017-0062. Review.

PMID:
29061101
20.

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.

Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, Iyer AK.

Front Pharmacol. 2017 Aug 23;8:561. doi: 10.3389/fphar.2017.00561. eCollection 2017. Review.

Supplemental Content

Loading ...
Support Center